Early CAR T cell expansion is associated with both therapeutic activity and inflammatory toxicity, such as cytokine release syndrome and neurotoxicity. Routine flow cytometry can reliably track ...

There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

CAR-T therapy was originally developed for leukemias and lymphomas, and the breakthrough treatment is now also being used for ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...

To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to analysts at William Blair.

A physician-scientist who last year joined the University of Colorado Cancer Center team will soon steer the first human ...

Only a few dozen patients with lupus have been treated with CAR-T-cell therapy — but in a small German study, all five ...

Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...